肿瘤相关的肾脏病：临床医生面临的新挑战
Tumor-Associated Renal Disease: New Challenges for Clinicians
DOI: 10.12677/ACM.2022.1281029, PDF,   
作者: 朱 君, 姜 军*：青海大学研究生院，青海 西宁
关键词: 肿瘤；肾脏病学；肿瘤肾脏病学；Cancer； Nephrology； Onco-Nephrology
摘要: 肿瘤肾脏学是肾脏病学中一个新的、不断发展的专科领域，主要研究癌症患者的肾脏疾病。随着许多新的癌症疗法出现在肿瘤学领域，癌症患者的生存时间比以往任何时候都要长。由于癌症的发生与发展不仅经常导致肾功能的异常，而且癌症治疗也往往会导致急性和慢性肾脏疾病，与癌症相关的肾脏并发症的发展与癌症较差的预后有关，而及时识别和开始治疗与改善这一人群的预后有关。因此，临床医生应该熟悉与癌症相关的肾脏并发症的诊断和处理，建立一个完整的关于癌症患者的慢性肾脏疾病的治疗体系。本文就肿瘤诊治过程中肾脏并发症的发生机制和肿瘤患者肾功能评估的方法等问题进行梳理与总结。
Abstract: Tumor nephrology is a new and growing field of nephrology, mainly studying kidney diseases in cancer patients. With many new cancer therapies emerging in oncology, cancer patients are living longer than ever before. Since the occurrence and progression of cancer often leads not only to ab-normal renal function, but also to acute and chronic kidney disease as a result of cancer treatment, the development of cancer-related renal complications is associated with a poorer prognosis of can-cer, and timely identification and initiation of treatment is associated with improved prognosis in this population. Therefore, clinicians should be familiar with the diagnosis and management of cancer-related renal complications and establish a complete treatment system for chronic kidney disease in cancer patients. In this paper, the mechanism of renal complications in the diagnosis and treatment of tumors and the methods of renal function evaluation in tumor patients were summa-rized.
文章引用：朱君, 姜军. 肿瘤相关的肾脏病：临床医生面临的新挑战[J]. 临床医学进展, 2022, 12(8): 7135-7141. https://doi.org/10.12677/ACM.2022.1281029

参考文献

[1] Xu, J., Murphy, S.L., Kochanek, K.D., et al. (2016) Deaths: Final Data for 2013. National Vital Statistics Reports, 64, 1-119.
[2] Malyszko, J., Kozlowski, L., Kozlowska, K., et al. (2017) Cancer and the Kidney: Dangereoux Liasons or Price Paid for the Progress in Medicine? Oncotarget, 8, 66601-66619. [Google Scholar] [CrossRef] [PubMed]
[3] Salahudeen, A.K. and Bonventre, J.V. (2013) Onconephrology: The Latest Frontier in the War against Kidney Disease. Journal of the American Society of Nephrology, 24, 26-30. [Google Scholar] [CrossRef] 
[4] Stewart, A.F. (2005) Clinical Practice. Hypercalcemia Associated with Cancer. The New England Journal of Medicine, 352, 373-379. [Google Scholar] [CrossRef] 
[5] Rosner, M.H. and Dalkin, A.C. (2014) Electrolyte Disorders Associ-ated with Cancer. Advances in Chronic Kidney Disease, 21, 7-17. [Google Scholar] [CrossRef] [PubMed]
[6] Chen, Y.-C., Sosnoski, D.M. and Mastro, A.M. (2010) Breast Cancer Metastasis to the Bone: Mechanisms of Bone Loss. Breast Cancer Research, 12, 215.
[7] Patel, A.M. and Goldfarb, S. (2010) Got Calcium? Welcome to the Calcium-Alkali Syndrome. Journal of the American Society of Neph-rology, 21, 1440-1443. [Google Scholar] [CrossRef] 
[8] Karras, A., De Montpreville, V., Fakhouri, F., et al. (2005) Renal and Thymic Pathology in Thymoma-Associated Nephropathy: Report of 21 Cases and Review of the Literature. Nephrology, Dialysis, Transplantation, 20, 1075-1082.
[9] Jhaveri, K.D., Shah, H.H., Patel, C., et al. (2014) Glomerular Diseases Associated with Cancer, Chemotherapy, and Hematopoietic Stem Cell Transplantation. Ad-vances in Chronic Kidney Disease, 21, 48-55. [Google Scholar] [CrossRef] [PubMed]
[10] Mallouk, A., Pham, P.-T.T. and Pham, P.-C.T. (2006) Concurrent FSGS and Hodgkin’s Lymphoma: Case Report and Literature Review on the Link between Nephrotic Glomerulopathies and Hematological Malignancies. Clinical and Experimental Nephrology, 10, 284-289. [Google Scholar] [CrossRef] [PubMed]
[11] Da’As, N., Polliack, A., Cohen, Y., et al. (2001) Kidney In-volvement and Renal Manifestations in Non-Hodgkin’s Lymphoma and Lymphocytic Leukemia: A Retrospective Study in 700 Patients. European Journal of Haematology, 67, 158-164. [Google Scholar] [CrossRef] [PubMed]
[12] Cairo, M.S. and Bishop, M. (2004) Tumour Lysis Syn-drome: New Therapeutic Strategies and Classification. British Journal of Haematology, 127, 3-11. [Google Scholar] [CrossRef] [PubMed]
[13] Howard, S.C., Jones, D.P. and Pui, C.-H. (2011) The Tu-mor Lysis Syndrome. New England Journal of Medicine, 364, 1844-1854. [Google Scholar] [CrossRef] 
[14] Shimada, M., Johnson, R.J., May, W.S., et al. (2009) A Novel Role for Uric Acid in Acute Kidney Injury Associated with Tumour Lysis Syndrome. Nephrology Dialysis Transplantation, 24, 2960-2964. [Google Scholar] [CrossRef] [PubMed]
[15] Laskin, B.L., Goebel, J., Davies, S.M., et al. (2011) Small Vessels, Big Trouble in the Kidneys and Beyond: Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Blood, 118, 1452-1462. [Google Scholar] [CrossRef] [PubMed]
[16] Besbas, N., Karpman, D., Landau, D., et al. (2006) A Classi-fication of Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Related Disorders. Kidney In-ternational, 70, 423-431. [Google Scholar] [CrossRef] [PubMed]
[17] Copelovitch, L. and Kaplan, B.S. (2008) The Thrombotic Microangiop-athies. Pediatric Nephrology, 23, 1761-1767. [Google Scholar] [CrossRef] [PubMed]
[18] Pankhurst, T., Savage, C.O.S., Gordon, C., et al. (2004) Malig-nancy Is Increased in ANCA-Associated Vasculitis. Rheumatology (Oxford, England), 43, 1532-1535. [Google Scholar] [CrossRef] [PubMed]
[19] Francis, K.K., Kalyanam, N., Terrell, D.R., et al. (2007) Dis-seminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a System-atic Review of Published Cases. The Oncologist, 12, 11-19. [Google Scholar] [CrossRef] [PubMed]
[20] Lam, A.Q. and Humphreys, B.D. (2012) Onco-Nephrology: AKI in the Cancer Patient. Clinical Journal of the American Society of Nephrology, 7, 1692-1700. [Google Scholar] [CrossRef] 
[21] Campbell, G.A., Hu, D. and Okusa, M.D. (2014) Acute Kidney Injury in the Cancer Patient. Advances in Chronic Kidney Disease, 21, 64-71. [Google Scholar] [CrossRef] [PubMed]
[22] Humphreys, B.D., Soiffer, R.J. and Magee, C.C. (2005) Renal Failure Associated with Cancer and Its Treatment: An Update. Journal of the American Society of Nephrology: JASN, 16, 151-161.
[23] Perazella, M.A. (2012) Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents. Clinical Journal of the American Society of Nephrology, 7, 1713-1721. [Google Scholar] [CrossRef] 
[24] Izzedine, H. and Perazella, M.A. (2017) Adverse Kidney Effects of Epidermal Growth Factor Receptor Inhibitors. Nephrology Dialysis Transplantation, 32, 1089-1097. [Google Scholar] [CrossRef] [PubMed]
[25] Izzedine, H., Mateus, C., Boutros, C., et al. (2017) Renal Effects of Immune Checkpoint Inhibitors. Nephrology Dialysis Transplantation, 32, 936-942.
[26] Launay-Vacher, V., Aapro, M., de Castro, G., et al. (2015) Renal Effects of Molecular Targeted Thera-pies in Oncology: A Review by the Cancer and the Kidney International Network (C-KIN). Annals of Oncology, 26, 1677-1684. [Google Scholar] [CrossRef] [PubMed]
[27] Launay-Vacher, V. and Deray, G. (2009) Hypertension and Pro-teinuria: A Class-Effect of Antiangiogenic Therapies. Anti-Cancer Drugs, 20, 81-82. [Google Scholar] [CrossRef] 
[28] van Cutsem, E., Tabernero, J., Lakomy, R., et al. (2012) Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients with Metastatic Colorectal Cancer Previously Treated with an Oxaliplatin-Based Regimen. Journal of Clinical Oncology, 30, 3499-3506. [Google Scholar] [CrossRef] 
[29] Kelly, R.J., Billemont, B. and Rixe, O. (2009) Renal Toxicity of Targeted Therapies. Targeted Oncology, 4, 121-133. [Google Scholar] [CrossRef] [PubMed]
[30] Hamid, O., Robert, C., Daud, A., et al. (2013) Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. New England Journal of Medicine, 369, 134-144. [Google Scholar] [CrossRef] 
[31] Hofmann, L., Forschner, A., Loquai, C., et al. (2016) Cutaneous, Gastrointestinal, Hepatic, Endocrine, and Renal Side-Effects of Anti-PD-1 Therapy. European Journal of Cancer, 60, 190-209.
[32] Shirali, A.C., Perazella, M.A. and Gettinger, S. (2016) Association of Acute Interstitial Nephritis with Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal of Kidney Diseases, 68, 287-291. [Google Scholar] [CrossRef] [PubMed]
[33] Cortazar, F.B., Marrone, K.A., Troxell, M.L., et al. (2016) Clini-copathological Features of Acute Kidney Injury Associated with Immune Checkpoint Inhibitors. Kidney International, 90, 638-647. [Google Scholar] [CrossRef] [PubMed]
[34] Levey, A.S., De Jong, P.E., Coresh, J., et al. (2011) The Definition, Classification, and Prognosis of Chronic Kidney Disease: A KDIGO Controversies Conference Report. Kidney Interna-tional, 80, 17-28. [Google Scholar] [CrossRef] [PubMed]
[35] Coresh, J., Astor, B.C., Greene, T., et al. (2003) Prevalence of Chronic Kidney Disease and Decreased Kidney Function in the Adult US Population: Third National Health and Nutrition Exam-ination Survey. American Journal of Kidney Diseases, 41, 1-12.
[36] Levey, A.S., Stevens, L.A., Schmid, C.H., et al. (2009) A New Equation to Estimate Glomerular Filtration Rate. Annals of Internal Medicine, 150, 604-612. [Google Scholar] [CrossRef] [PubMed]
[37] Collins, A.J., Li, S., Gilbertson, D.T., et al. (2003) Chronic Kidney Disease and Cardiovascular Disease in the Medicare Population. Kidney International Supple-ment, 87, S24-531.
[38] Funakoshi, Y., Fujiwara, Y., Kiyota, N., et al. (2016) Validity of New Methods to Evaluate Renal Function in Cancer Patients Treated with Cisplatin. Cancer Chemotherapy and Pharmacology, 77, 281-288. [Google Scholar] [CrossRef] [PubMed]
[39] Janowitz, T., Williams, E.H., Marshall, A., et al. (2017) New Model for Estimating Glomerular Filtration Rate in Patients with Cancer. Journal of Clinical Oncology, 35, 2798-2805.

为你推荐